Sukses Main Mahjong Ways Best808 Pahami Scatter dan Kombinasinya Mahjong Ways Best808 Simbol Scatter Meningkatkan Peluang Menang Kesalahan Umum Pemain Mahjong Ways di Best808 Auto Jackpot Strategi Terbaik Fitur Scatter Mahjong Ways Best808 Mahjong Ways Best808 Panduan Scatter Wild Hasil Maksimal Pola Mahjong Ways Best808 Gacor Scatter Menang Bongkar Misteri Mahjong Ways Best808 Kunci Kemenanganmu Mau Cuan Maksimal di Mahjong Ways Best808 Trik Menggunakan Scatter Agar Lebih Untung Main Mahjong Ways di Best808 Kenali Pola Scatter Free Spin Gandakan Kemenanganmu Rahasia Scatter Mahjong Ways Best808 Strategi Jitu Menang Jackpot Besar Misteri Scatter Mahjong Ways Tol777 Kunci Jackpot Besar Bongkar Rahasia Mahjong Ways Tol777 Fitur Scatter Pola Menang Mahjong Ways Tol777 Simbol Scatter Kemenangan Besar Main Mahjong Ways di Tol777 Cara Memanfaatkan Scatter Strategi Mahjong Ways Tol777 Rahasia Scatter Trik Menang Jackpot Analisis Pola Permainan Mahjong Ways Keunggulan Mahjong Ways Tol777 vs Tradisional Kombinasi Simbol Tertinggi Mahjong Ways Langkah Meningkatkan Keahlian Mahjong Ways Mahjong Ways Tol777 Berbeda dari Permainan Mengapa Mahjong Ways Tol777 Diminati Dunia Optimalkan Putaran Mahjong Ways Tol777 Sejarah Mahjong Ways Tol777 dan Keunikan Simbol Mahjong Ways Tol777 dan Pemanfaatannya Strategi Lanjutan Mahjong Ways Tol777 Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Cara Cepat Kuasai Mahjong Ways Tol777 Mengapa Mahjong Ways Tol777 Populer Mitos & Fakta Mahjong Ways Tol777 Strategi Pemula vs Pro Mahjong Ways Teknik Profesional Mahjong Ways Tol777 Mahjong Ways Tol777: Keberuntungan atau Skill? Mahjong Ways Tol777: Tradisi dan Inovasi Panduan Mahjong Ways Tol777 untuk Pemula Rahasia Menang Mahjong Ways Tol777 Tips Efektif Main Mahjong Ways Tol777 Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online main mahjong ways di malam hari jackpot profit mengamati permainan mahjong ways dengan baik dan benar merasa bosan pada malam hari? coba cara bermain mahjong ways ini minum kopi memotivasi bermain mahjong ways nelayan tebing tinggi pola mahjong ways hasil mencengangkan pelajar bandung download mahjong ways peluang besar trik dan pola mahjong ways pemuda belanda tato mahjong ways mengenang jackpot satu miliar pola rtp mahjong ways terbaik resep bermain mahjong ways dengan mudah slot mahjong ways dikenal sejak abad ke-11 hingga zaman milenial video mahjong ways viral menghebohkan warga indonesia warga jayamakmur dulu diremehkan, bermain mahjong ways hidup berlimpah harta unik keren bali cendera mata mahjong ways rp100000 warga bingung merek cat dinding sama mahjong ways

Medicare Drug Benefit is Weakened by Congressional Budget Deal

Congress has undermined the Medicare drug benefit that millions of older Americans depend on – one of the few federal health care programs that’s working well.

The two-year federal budget deal passed recently shifts more of the program’s costs onto drug manufacturers starting in 2020. In the process, the change eliminates one of the key features that has made the program – known as Part D – successful for over a decade.

If the change stays in place, Part D could soon become just another budget-busting entitlement with little hope of long-term sustainability.

Medicare Part D provides private, federally subsidized prescription drug coverage to 42 million senior citizens. And since being implemented in 2006, the program has served beneficiaries extraordinarily well. In one recent survey, 87 percent of enrollees reported being satisfied with their Part D coverage.

Such positive attitudes are largely the result of Part D’s market-based structure, which provides patients with a wide array of coverage options. This year, the average enrollee had 23 stand-alone plans to pick from. This setup forces insurers to compete with one another for seniors’ business by offering the highest-quality, lowest-cost plans possible.

The program has also proven surprisingly affordable for taxpayers. A recent analysis from the American Action Forum found that the program’s 2016 costs were less than half what was projected when the law was first implemented.

That’s an unheard of feat for a federal program. One of the main reasons costs have remained so low? Plan providers are encouraged to keep patient drug expenses under control.

Under the standard benefit model, enrollees pay for the full price of their drugs until they reach a deductible of $405. After that, they’re responsible for only a quarter of drug costs up to a certain limit – $3,750 this year.

It’s at this point that beneficiaries enter a gap in coverage known as the “donut hole” in which they will pay 35 percent of a brand name medicine’s cost in 2018. Once drug spending reaches about $5,000, patients are in the catastrophic phase of coverage, and cost-sharing drops off once again.

ObamaCare established a plan to phase out this donut hole by 2020 so that seniors would only have to pay 25 percent of brand-name drug costs after meeting their deductible. The remaining 75 percent of the cost would be split between pharmaceutical companies – which would discount drugs by 50 percent – and insurers that would cover the other 25 percent.

By making plan providers responsible for such a significant share of donut hole spending, the reform gives these companies a powerful incentive to keep as many patients as possible out of the donut hole. After all, once patients reach the donut hole, insurers see their costs soar. It’s for this reason that three in four Part D enrollees never enter the coverage gap.

The budget deal effectively obliterates that incentive – and thus threatens the program’s long-term sustainability. It does this by shifting the vast majority of donut hole spending onto drug companies and letting insurers almost entirely off the hook. As of 2020, plan providers will only be responsible for 5 percent of a brand-name drug’s cost in the coverage gap, while pharmaceutical makers will have to pay for 70 percent.

The consequences for Part D could be catastrophic. Insurers will actually have an incentive to drive patient drug spending over the donut-hole threshold as quickly as possible by, for instance, encouraging patients to rely on costly brand-name drugs instead of more affordable generics. Once patients enter the coverage gap, insurer costs would plummet.

What’s remarkable about this change is that it’s a far better deal for insurance companies than for patients or taxpayers. A recent analysis by the consulting firm Avalere estimates that the government will save $7 billion over the next decade thanks to these changes. The average Part D beneficiary will save $20 a year. Insurers, meanwhile, will save a whopping $40 billion.

Insurance companies don’t deserve another government handout. And Americans don’t deserve another unsustainable entitlement program. Lawmakers need to roll back these misguided changes and rescue Part D from its impending fiscal ruin.

Read more . . .

Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.

Scroll to Top